v3.26.1
Segment information - Schedule of Segment Results (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Disclosure of geographical areas [line items]    
Net sales € 22,106 € 19,889
Other revenues 1,438 1,452
Cost of sales (6,155) (5,881)
Research and development expenses (3,980) (3,717)
Selling and general expenses (4,792) (4,506)
Net income attributable to non-controlling interests 40 25
Biopharma    
Disclosure of geographical areas [line items]    
Net sales € 22,106 19,889
Change in revenue, on a reported basis (IFRS), percentage 11.10%  
Change in revenue, at constant exchange rates non-IFRS, percentage 15.70%  
Other revenues € 1,168 1,246
Change in other revenue, on a reported basis (IFRS), percentage (6.30%)  
Change in other revenue, at constant exchange rates non-IFRS, percentage (2.00%)  
Cost of sales € (5,812) (5,753)
Change in cost of sales, on a reported basis (IFRS), percentage 1.00%  
Change in cost of sales, at constant exchange rates non-IFRS, percentage 3.80%  
Research and development expenses € (3,979) (3,716)
Change in research and development expenses, on a reported basis (IFRS), percentage 7.10%  
Change in research and development expenses, at constant exchange rates non-IFRS, percentage 9.90%  
Selling and general expenses € (4,690) (4,447)
Change in selling and general expenses, on a reported basis (IFRS), percentage 5.50%  
Change in selling and general expenses, at constant exchange rates non-IFRS, percentage 9.40%  
Other operating income and expenses € (2,630) (1,941)
Share of profit/(loss) from investments accounted for using the equity method 74 77
Net income attributable to non-controlling interests (7) (8)
Business operating income € 6,230 5,347
Change in business operating income, on a reported basis (IFRS), percentage 16.50%  
Change in business operating income, at constant exchange rates non-IFRS, percentage 22.20%  
      As % of net sales 28.20%  
Other    
Disclosure of geographical areas [line items]    
Net sales  
Other revenues € 270 206
Change in other revenue, on a reported basis (IFRS), percentage 31.10%  
Change in other revenue, at constant exchange rates non-IFRS, percentage 31.10%  
Cost of sales € (133) (128)
Change in cost of sales, on a reported basis (IFRS), percentage 3.90%  
Change in cost of sales, at constant exchange rates non-IFRS, percentage 3.10%  
Research and development expenses € (1) (1)
Change in research and development expenses, on a reported basis (IFRS), percentage 0.00%  
Change in research and development expenses, at constant exchange rates non-IFRS, percentage 0.00%  
Selling and general expenses € (102) (59)
Change in selling and general expenses, on a reported basis (IFRS), percentage 72.90%  
Change in selling and general expenses, at constant exchange rates non-IFRS, percentage 76.30%  
Other operating income and expenses € (6) (2)
Share of profit/(loss) from investments accounted for using the equity method 0
Net income attributable to non-controlling interests 0
Business operating income € 28 16
Change in business operating income, on a reported basis (IFRS), percentage 75.00%  
Change in business operating income, at constant exchange rates non-IFRS, percentage 68.80%  
Total    
Disclosure of geographical areas [line items]    
Net sales € 22,106 19,889
Change in revenue, on a reported basis (IFRS), percentage 11.10%  
Change in revenue, at constant exchange rates non-IFRS, percentage 15.70%  
Other revenues € 1,438 1,452
Change in other revenue, on a reported basis (IFRS), percentage (1.00%)  
Change in other revenue, at constant exchange rates non-IFRS, percentage 2.70%  
Cost of sales € (5,945) (5,881)
Change in cost of sales, on a reported basis (IFRS), percentage 1.10%  
Change in cost of sales, at constant exchange rates non-IFRS, percentage 3.80%  
Research and development expenses € (3,980) (3,717)
Change in research and development expenses, on a reported basis (IFRS), percentage 7.10%  
Change in research and development expenses, at constant exchange rates non-IFRS, percentage 9.90%  
Selling and general expenses € (4,792) (4,506)
Change in selling and general expenses, on a reported basis (IFRS), percentage 6.30%  
Change in selling and general expenses, at constant exchange rates non-IFRS, percentage 10.30%  
Other operating income and expenses € (2,636) (1,943)
Share of profit/(loss) from investments accounted for using the equity method 74 77
Net income attributable to non-controlling interests (7) (8)
Business operating income € 6,258 € 5,363
Change in business operating income, on a reported basis (IFRS), percentage 16.70%  
Change in business operating income, at constant exchange rates non-IFRS, percentage 22.30%  
      As % of net sales 28.30%